Use of a Professional Practice Model to Illuminate the Importance of Relationships

2014 ◽  
Vol 20 (2) ◽  
pp. 127-136 ◽  
Author(s):  
Linda Johnson ◽  
Jamie Ezekielian
Keyword(s):  
Professional Practice ◽  
Ohio State University ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
State University ◽  
Practice Model ◽  
Nurse Satisfaction ◽  
Primary Nursing ◽  
The Ohio State University ◽  
Frontline Leaders

At the Ohio State University Comprehensive Cancer Center—James Cancer Hospital and Solove Research Institute (OSUCCC—James), implementation of relationship-based care (RBC) and primary nursing (PN) along with enculturation of the James Nursing professional practice model (PPM), have improved patient and nurse satisfaction. This article describes the importance of relationships with self, colleagues, patients and families, and the community. Best practices and outcomes are shared to inspire others who seek to transform professional practice environments and organizational cultures by focusing on patients and families and engaging frontline leaders in the change process.

The formulary process for biosimilar additions at a comprehensive cancer center

2021 ◽  
pp. 107815522110367
Author(s):  
Lauren M Aschermann ◽  
Charlotte M Forshay ◽  
Julie Kennerly-Shah ◽  
Jeffrey Pilz
Keyword(s):  
Access To Care ◽  
Cancer Care ◽  
Biologic Agents ◽  
Ohio State University ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
State University ◽  
Patients With Cancer ◽  
Oncology Care ◽  
The Ohio State University

Biological products may be used to diagnose, prevent, treat, and cure diseases and medical conditions, including cancer. Biosimilar agents, approved under an abbreviated 351(k) pathway, continue to increase in number and market share for biologic agents, especially for cancer care. Although biosimilars offer the potential for improved access to care, their introduction to the marketplace has created significant disruption. It is imperative that health systems providing care to patients with cancer develop a well-defined process to address the challenges associated with biosimilars. This descriptive article outlines pharmacy considerations for biosimilars and describes the current practices at The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University. Biosimilars have and will continue to significantly impact oncology care. Organizations must understand the clinical, operational, and financial challenges associated with the use of these products.

scholarly journals LPTO-10. ASSESSMENT OF LEPTOMENINGEAL CARCINOMATOSIS DIAGNOSIS AND OUTCOMES FROM 2005 TO 2015 AT THE OHIO STATE UNIVERSITY

2019 ◽  
Vol 1 (Supplement_1) ◽  
pp. i8-i8
Author(s):  
Nicole Williams ◽  
Hannah Rinehardt ◽  
Evan Morgan ◽  
Mahmoud Kassem ◽  
Marilly Palettas ◽  
...  
Keyword(s):  
Leptomeningeal Carcinomatosis ◽  
Ohio State University ◽  
Diagnostic Methods ◽  
Detection Methods ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Primary Cancer ◽  
State University ◽  
Csf Cytology ◽  
The Ohio State University

Abstract BACKGROUND: Leptomeningeal carcinomatosis (LMC) is a complication of solid tumor malignancies where tumors metastasize to the leptomeninges. LMC complicates 4–15% of malignancies with incidence increasing as survival of patients with advanced cancer improves. Diagnostic methods include magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) cytology. We assessed detection methods, incidence, and outcomes of LMC at The Ohio State University Comprehensive Cancer Center from 2005–2015. METHODS: This was a single-institution retrospective study of 160 patients with confirmed diagnosis of LMC. Patients with hematologic and central nervous system malignancies were excluded. Descriptive statistics were used to summarize demographic and clinical characteristics. Overall survival (OS) was defined as time from LMC diagnosis to death or last known follow-up, and was generated using Kaplan-Meier methods. RESULTS: Median age of LMC diagnosis was 55.8 years (range: 48, 62.5). 69 (43%) patients had primary breast cancer, 41 (26%) had lung cancer, and 17 (11%) had melanoma. 73 patients (46%) presented with stage IV disease at initial diagnosis of the primary cancer, 41 (26%) with stage III disease, and 26 (16%) with stage II disease. Median time from diagnosis of primary cancer to diagnosis of LMC was 2 years (range: 0, 31.2). 158 (99%) patients had metastases at the time of LMC diagnosis, predominantly in bone (36%) or brain (36%). Median OS was 1.9 months (CI: 1.3, 2.5). 160 (100%) patients had an MRI of the brain or spine and 155 (97%) had MRI findings consistent with LMC. 75 (47%) patients underwent lumbar puncture, and 39 (52%) had CSF cytology positive for malignancy. CONCLUSIONS: Despite treatment, prognosis remains poor and confirmation of diagnosis can be challenging. This study highlights the need for novel therapeutics and improved diagnostic techniques for patients with LMC.

QIM19-143: Reducing Risk of IV Chemotherapy Administration Errors Utilizing Pump Integration Technology

2019 ◽  
Vol 17 (3.5) ◽  
pp. QIM19-143
Author(s):  
Robert C. Stillman ◽  
Emily Konerman
Keyword(s):  
Patient Safety ◽  
Medical Center ◽  
Ohio State University ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
State University ◽  
Cancer Hospital ◽  
The Ohio State University ◽  
Smart Pump ◽  
Research Institute

Background: The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solve Research Institute is a 356-bed cancer care hospital that is part of The Ohio State University Medical Center. In addition to the inpatient beds, the hospital services 175 ambulatory infusion chairs. Each month, we administer over 6,000 chemotherapy infusions on an IV pump. Smart IV pumps in tandem with hospital information technology infrastructure integrate IV drug administration pump data with the electronic medical record (EMR) and computerized physician order entry to decrease risk of error and increase patient safety. The closed loop system transmits the medication infusion rate and the prescribed dose to the smart pump to deliver the medication. The smart pump in turn transmits the dose and volume delivered to the EMR to accurately capture what the patient received. The ability to wirelessly transmit clinical information from the EMR to automatically program the IV pump with specific data was implemented in March 2018 as part of a system-wide safety initiative to enhance patient safety via the reduction of error during medication administration. Methods: IV pump integration has been in use since March 2018; the organization has robust data on the use of smart pump technology that allowed for comparison of data pre- and postimplementation of pump integration. This includes: total suite usage, count of basic infusions, severe harm averted, total good catches, and event-reporting data. Post-integration, the overall compliance of utilizing pump integration (sending an order from the EMR to the smart IV pump) is also continuously monitored. Results: The implementation of pump interoperability resulted in a safer delivery of infused medications (Figure 1). The use of “basic Infusion” or unprotected infusion function decreased while our use of the appropriate safeguarded pump program increased. The compliance at the medical center increased from about 86% to almost 94%. With increased usage of the pump interoperability, the potential for severe harm as well as human programming errors decreased significantly. Conclusion: The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solve Research Institute is able to deliver infused medications via a smart pump in a safer, more automated system with the implementation of pump integration. We are able to reduce the “human factor” in medication delivery by reducing keystrokes and opportunities for manual programming errors. Pre-integration data cannot be isolated for the cancer hospital only, from our post-implementation data we can infer that our chemotherapy infusions are subsequently safer for our patients.

scholarly journals NCMP-07. TREATMENT-INDUCED CEREBRAL NECROSIS IN GLIOMAS: THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER (OSUCCC) EXPERIENCE

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii124-ii124
Author(s):  
Appaji Rayi ◽  
Iyad Alnahhas ◽  
Joshua Palmer ◽  
Raju Raval ◽  
Wayne Slone ◽  
...  
Keyword(s):  
Promoter Hypermethylation ◽  
Ohio State University ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
Idh Mutation ◽  
State University ◽  
Grade Ii ◽  
Previously Treated ◽  
The Ohio State University ◽  
Cerebral Necrosis

Abstract INTRODUCTION Treatment-induced cerebral necrosis (TN) is a challenging complication encountered in neuro-oncology. Diagnosis and treatment of TN remains poorly defined. METHODS In this single institution, retrospective study, consecutive patients with gliomas and TN between 01/01/2012 and 04/20/2020 at the OSUCCC were identified. Details of the tumor treatment, molecular markers, radiological and pathological findings of TN, as well as treatment, recurrence rate and management upon recurrence were collected. RESULTS Of the 53 patients analyzed, 37 had glioblastoma, 7 had anaplastic oligodendroglioma and 9 had grade II or III astrocytoma. MGMT promoter hypermethylation was present in 31/50 (59%) and IDH mutation in 17/53 (32%). Diagnosis of TN was based on histology in 43/53 (81%) or clinical/radiographic features in 10/53 (19%). Worsening of focal weakness (36%), seizures (9%) or being (30%) were common presentations at TN diagnosis. Patient with right compared to left hemisphere involvement were more symptomatic at TN diagnosis. (p=0.049). Bevacizumab (BEV) (51%), resection (28%), steroids only (9%) or Laser Interstitial Thermal Therapy (6%) were used to treat TN. Steroids were weaned off in 20/27 (74%) after receiving BEV. Among all treatments, BEV was significantly associated with a better outcome (resolution or partial improvement of enhancement in 84.6%) (p=0.0006, Bonferroni corrected p< 0.005). TN Recurrence occurred in 36%, 70% and 100% of the patients treated with BEV, resection and LITT respectively. The median duration to TN recurrence was 10 weeks (range: 3–70 weeks). Initial treatment used for TN, MGMT methylation and IDH mutation status did not predict TN recurrence. (p=0.074; p=0.819; p=0.607 respectively). CONCLUSIONS BEV appears to be a superior treatment to control TN overall. Recurrence of TN in patients previously treated with BEV was 36%. There was no difference in the risk of developing recurrent TN based on MGMT or IDH status.

scholarly journals Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients

2021 ◽  
Vol 10 ◽  
Author(s):  
Francesca Cottini ◽  
Ying Huang ◽  
Nita Williams ◽  
Naresh Bumma ◽  
Abdullah M. Khan ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Absolute Lymphocyte Count ◽  
Comprehensive Cancer Center ◽  
Cancer Center ◽  
State University ◽  
Incurable Disease ◽  
Limited Life ◽  
Prophylactic Measures ◽  
Causes Of Mortality ◽  
The Ohio State University

Multiple myeloma (MM) is an incurable disease with a limited life expectancy of five years from diagnosis. Uncontrolled disease or infections are the main causes of mortality. Daratumumab, a monoclonal antibody against CD38, is approved to treat patients with MM. Its target, CD38, is expressed not only on MM cells but also on common lymphoid precursors and subsets of normal lymphocytes. Daratumumab-induced lymphopenia is common, but its clinical significance is understudied. In this study, we report the baseline characteristics, rates of severe lymphopenia, infections, and clinical trajectory of multiple myeloma patients (n = 100) treated with daratumumab-based regimens at the Ohio State University Comprehensive Cancer Center. We discover high rates of infections, hospital utilization, and severe lymphopenia and identify risks factors for severe lymphopenia, such as low pretreatment absolute lymphocyte count (ALC) values. Severe lymphopenia persists in 23% of patients, resulting in worst survival outcomes. Our data underline the importance of monitoring ALC and consider future use of prophylactic measures or alternative regimens in subsets of MM patients.

Sign in / Sign up

Export Citation Format

Share Document